Cargando…
Scientific Validation and Clinical Application of Lung Cancer Organoids
Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of nor...
Autores principales: | Lee, Dahye, Kim, Yoonjoo, Chung, Chaeuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616085/ https://www.ncbi.nlm.nih.gov/pubmed/34831235 http://dx.doi.org/10.3390/cells10113012 |
Ejemplares similares
-
New Insights into the Clinical Implications of Yes-Associated Protein in Lung Cancer: Roles in Drug Resistance, Tumor Immunity, Autophagy, and Organoid Development
por: Yoo, Geon, et al.
Publicado: (2021) -
Cryobiopsy: A Breakthrough Strategy for Clinical Utilization of Lung Cancer Organoids
por: Park, Dongil, et al.
Publicado: (2023) -
Transthoracic Needle Biopsy: How to Maximize Diagnostic Accuracy and Minimize Complications
por: Chung, Chaeuk, et al.
Publicado: (2020) -
Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report
por: Kim, Yoonjoo, et al.
Publicado: (2022) -
Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
por: Yeo, Min-Kyung, et al.
Publicado: (2022)